Claims for Patent: 11,141,388

Summary for Patent: 11,141,388

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	17/103,819
Patent Claims:	1. A method of treating major depressive disorder, comprising orally administering a dosage form once or twice a day for at least 8 consecutive days to a human being suffering with a symptom of major depressive disorder; wherein the dosage form comprises, as the only therapeutically active compounds in the dosage form: 1) about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form, and 2) about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form; and wherein the dosage form provides sustained release of bupropion. 2. The method of claim 1, wherein the dosage form comprises bupropion hydrochloride and dextromethorphan hydrobromide. 3. The method of claim 1, wherein after orally administering the dosage form, the human being experiences an improvement in a depressive symptom as compared to baseline. 4. The method of claim 1, wherein orally administering the dosage form is more effective in treating major depressive disorder than orally administering a placebo. 5. The method of claim 1, wherein the dosage form is orally administered once daily. 6. The method of claim 1, wherein the dosage form is orally administered twice daily. 7. The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days. 8. The method of claim 1, wherein the dosage form is orally administered for at least 30 consecutive days. 9. The method of claim 1, wherein the dosage form is orally administered once a day for 1 day and twice a day thereafter. 10. The method of claim 1, wherein the dosage form is orally administered once a day for 2 days and twice a day thereafter. 11. The method of claim 1, wherein the dosage form is orally administered once a day for 3 days and twice a day thereafter. 12. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anxiety. 13. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in improving concentration, reducing mental slowing, or a combination thereof. 14. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in improving mood, reducing feelings of intense sadness, reducing despair, reducing pessimistic worry, or a combination thereof. 15. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing agitation, irritability, restlessness, or a combination thereof. 16. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing guilt, feelings of worthlessness, self-deprecation, or a combination thereof. 17. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anger or reckless behavior. 18. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing suicidal thoughts or attempts, or a combination thereof. 19. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing insomnia. 20. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anorexia, appetite loss, weight loss, or a combination thereof. 21. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing weight gain. 22. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing decreased energy, fatigue, decreased libido, or a combination thereof. 23. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing aches, pains, headaches, cramps, or a combination thereof. 24. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing digestive issues. 25. The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing abnormal hormonal circadian rhythms. 26. The method of claim 1, wherein the human being is at least 18 years of age. 27. The method of claim 1, wherein the dosage form further comprises a pharmaceutically acceptable excipient.